Robust calibrations on reduced sample sets for API content prediction in tablets: definition of a cost-effective NIR model development strategy by Pieters, Sigrid et al.
  
biblio.ugent.be 
 
The UGent Institutional Repository is the electronic archiving and dissemination platform for all 
UGent research publications. Ghent University has implemented a mandate stipulating that all 
academic publications of UGent researchers should be deposited and archived in this repository. 
Except for items where current copyright restrictions apply, these papers are available in Open 
Access. 
 
This item is the archived peer-reviewed author-version of: Robust calibrations on reduced 
sample sets for API content prediction in tablets: Definition of a cost-effective NIR model 
development strategy  
Authors: Sigrid Pieters, Wouter Saeys, Tom Van den Kerkhof, Mohammad Goodarzi, Mario 
Hellings, Thomas De Beer, Yvan Vander Heyden           
In: Analytica Chimica Acta, 761, 62-70 (2013) 
 
Optional: link to the article  
 
To refer to or to cite this work, please use the citation to the published version: 
Authors (year). Title. journal Volume(Issue)  page-page. Doi 10.1016/j.aca.2012.11.034    
1 
 
Robust calibrations on reduced sample sets for API content prediction in tablets: Definition of a 1 
cost-effective NIR model development strategy 2 
 3 
Sigrid Pieters1, Wouter Saeys2, Tom Van den Kerkhof3, Mohammad Goodarzi2, Mario Hellings3, 4 
Thomas De Beer4, Yvan Vander Heyden1 5 
 6 
1 Department of Analytical Chemistry and Pharmaceutical Technology, Center for Pharmaceutical 7 
Research, Vrije Universiteit Brussel - VUB, Laarbeeklaan 103, B-1090 Brussels, Belgium 8 
2 Department of Biosystems, Faculty of Bioscience Engineering, Katholieke Universiteit Leuven – 9 
KULeuven, Kasteelpark Arenberg 30, B-3001 Heverlee, Belgium 10 
3 ChemPhar development Johnson & Johnson, Turnhoutseweg 30, B-2340 Beerse, Belgium 11 
4 Laboratory of Pharmaceutical Process Analytical Technology, Universiteit Gent, Harelbekestraat 72, 12 
B-9000 Ghent, Belgium13 
 14 
 15 
* Corresponding author: Tel.: +32 2 477 47 34 16 
    Fax: +32 2 477 47 35 17 
    Email: yvanvdh@vub.ac.be (Y. Vander Heyden) 18 
 19 
Keywords: near infrared spectroscopy, prior spectral information, tablets, orthogonal projection 20 
methods,  augmentation methods 21 
 22 
Abstract 23 
 24 
Owing to spectral variations from other sources than the component of interest, large investments in 25 
the NIR model development may be required to obtain satisfactory and robust prediction 26 
performance. To make the NIR model development for routine active pharmaceutical ingredient 27 
(API) prediction in tablets more cost-effective, alternative modelling strategies were proposed. They 28 
used a massive amount of prior spectral information on intra- and inter-batch variation and the pure 29 
component spectra to define a clutter, i.e. the detrimental spectral information. This was 30 
subsequently used for artificial data augmentation and/or orthogonal projections. The model 31 
performance improved statistically significantly, with a 34-40% reduction in RMSEP while needing 32 
fewer model latent variables, by applying the following procedure before PLS regression: (1) 33 
augmentation of the calibration spectra with the spectral shapes from the clutter, and (2) net analyte 34 
pre-processing (NAP). The improved prediction performance was not compromised when reducing 35 
the variability in the calibration set, making exhaustive calibration unnecessary. Strong water content 36 
variations in the tablets caused frequency shifts of the API absorption signals that could not be 37 
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included in the clutter. Updating the model for this kind of variation demonstrated that the 1 
completeness of the clutter is critical for the performance of these models and that the model will 2 
only be more robust for spectral variation that is not co-linear with the one from the property of 3 
interest. 4 
 5 
1. Introduction 6 
 7 
Together with the growing popularity of near-infrared (NIR) spectroscopy, the interest to use 8 
multivariate prediction models (e.g. PLS) emerged in different industries (food, chemical, 9 
pharmaceutical…) [1-3]. Compared to HPLC, NIR spectroscopy provides a non-destructive, extremely 10 
fast, and hands-on analysis, which can substantially reduce analysis times and costs for the routine 11 
assay of active pharmaceutical ingredient (API) in tablets. Multivariate calibration models (e.g. PLS) 12 
are typically built in an empirical way. Although this may offer flexibility, it can also be a drawback 13 
making the model development, maintenance and update more complex [4]. Consequently, more 14 
investment may be required, which must guarantee that a low prediction error is obtained and 15 
maintained for future predictions of novel batches.  16 
There are numerous examples where spectral disturbances from various sources, e.g. 17 
variations in a process, temperature, humidity... , upset the model predictions. In this paper, we 18 
specifically consider this problem in tablets produced from a routine production line. Besides 19 
measurement variability (path length, temperature...), systematic changes in the measured signals in 20 
the spectra of tablets may appear, e.g. originating from process and raw material variability (inter- 21 
and intra-batch effects). A tableting process involves different subsequent processing steps, such as 22 
mixing the ingredients, granulation, compaction and coating. Some tablet production variables, e.g. 23 
grain size, compaction pressure, and coating thickness, may introduce spectral variability that is 24 
irrelevant for predicting the API content in the tablets [5]. Also, the excipients in the tablet can vary 25 
slightly between different batches or samples (excipient homogeneity), while the tablet composition 26 
can vary as well when different API target concentration levels are considered in the model. 27 
Depending on the relative humidity conditions during their production, packaging, storage and 28 
analysis, the water content is another important variable that may upset the NIR model predictions 29 
[6]. 30 
It is evident that when more relevant variation is covered by the calibration set of the NIR 31 
model, lower prediction errors can be obtained on new independent samples [7]. Including all the 32 
expected variation in the calibration set is the most intuitive way for doing this, and is still 33 
recommended by regulatory authorities [8]. Drawbacks of this approach are that the model 34 
complexity may increase rapidly when more 'non-relevant' spectral variability is included in the 35 
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exhaustive calibration, needing additional latent variables or introducing non-linearities that may 1 
require non-linear calibration techniques. A more important practical problem is that a substantial 2 
number of well-chosen samples, describing all the expected variability, is needed to obtain robust 3 
model performance. It is a non-trivial task to obtain a good estimate of the expected variation in the 4 
samples to be predicted, also because there is a practical limit (particularly in terms of costs) to the 5 
number of samples to be analysed with the reference technique. Hence, in most practical cases one 6 
selects randomly the calibration samples from 'representative' batches. As a result, existing 7 
calibration bases rarely contain all the relevant variability from all the influence factors which can 8 
occur in industrial conditions [9], making the models less robust for their long term use and requiring 9 
frequently model updates.   10 
It is often overlooked that one of the major advantages of NIR spectroscopy, i.e. its analysis 11 
speed and simplicity, provides an excellent opportunity to measure significantly more dosage units 12 
than what would be possible with the reference technique, i.e. HPLC. This is especially the case when 13 
automated NIR equipment is available. Hence, a massive amount of spectral information can be 14 
obtained easily to allow a better understanding of the possible spectral perturbations. The aim of the 15 
present study is to investigate whether the use of such spectral information on intra- and inter-batch 16 
variation (without corresponding reference analyses) during model development can improve the 17 
NIR model performance for predicting the API content in tablets from novel batches. The prediction 18 
performance of different approaches using the prior spectral information was compared to that of 19 
PLS models. It was also investigated whether these strategies allowed reducing the variability in the 20 
calibration set without compromising the prediction performance. This should lead to the definition 21 
of a cost-effective strategy for developing robust calibration models for the routine prediction of API 22 
in tablets. 23 
 24 
2. Theory 25 
 26 
There are different ways to incorporate prior information into the calibration model. One 27 
distinguishes augmentation and orthogonal correction methods (supervised and unsupervised), 28 
while combinations of these are possible as well. 29 
 30 
2.1. Augmentation methods 31 
 32 
2.1.1. Noise augmentation in PLS 33 
The idea of noise augmentation (NA) or ensemble methods [10-13] is to expand the 34 
calibration set artificially in order to build PLS models that are more robust to the different kinds of 35 
4 
 
variability expected in the future sample population. An artificial calibration set can be created by 1 
augmenting the original one with a high number of spectral signatures, representing the ‘noise’. The 2 
original spectra in the resulting calibration set should span the chemical variation in the best possible 3 
way, whereas the perturbation spectra should represent all the other possible variations that can be 4 
expected. One way to estimate the latter is through the measurement of spectra under varying 5 
perturbation conditions. Because the 'noise' added to the calibration spectra should be independent 6 
from the component of interest, this operation should not change the corresponding reference 7 
values.  8 
 9 
2.1.2. Prediction – Augmented Classical Least Squares (P-ACLS) 10 
 In contrast to the inverse modeling approaches (e.g. PLS), classical least squares (CLS) 11 
regression is based on an explicit linear additive model (e.g. Lambert-Beer's law in spectroscopy). 12 
Equation (1) depicts the CLS model. 13 
 14 
J = PK + EA      (1) 15 
 16 
where J is the matrix of the measured intensities, P is the matrix of concentration values, K is the 17 
matrix of the pure component signals at unit concentration, and EA the model error. 18 
 The major weakness of CLS is that it requires quantitative knowledge of all the spectrally 19 
active components in the calibration set to get an estimate of K. Augmented (A)-CLS attempts to 20 
obtain a better estimation of K by augmenting the predicted pure component matrix with empirically 21 
derived spectral shapes, e.g. the loading vectors from PCA on the spectral residuals EA (SRACLS), 22 
known pure component spectra [14], or a priori known other variation not included in the calibration 23 
set (PACLS) [15-16]. The addition of the spectral shapes both changes and corrects the concentration 24 
estimates for the component of interest.  25 
 26 
2.2. Orthogonal correction methods 27 
 28 
2.2.1. Orthogonal projections 29 
 There are essentially 2 contributions within the calibration matrix X, i.e. one originating from 30 
the analyte of interest k (Xk), and another from all other sources of variance (X-k).  31 
 32 
kk −+= XXX       (2) 33 
 34 
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Pretreatments based on orthogonal projections aim at removing those spectral patterns, which are 1 
'interfering' with the desired prediction from the data matrix X, before calibration on y. It is 2 
attempted to return the spectra of X as X*, containing the most condensed spectral information, i.e. 3 
the net analyte signal (Xk) [17]. The information to be removed, i.e. the clutter, can be defined based 4 
on pure component spectra of known interferences [18], an experimental design with varying 5 
perturbation factor(s) [19], or an (augmented) calibration data set [12]. The column vectors of the so 6 
obtained matrix S form a basis of the detrimental subspace. Then, an orthogonal projector to S, i.e. 7 
⊥
SP , can be calculated to correct the initial matrix X as follows. 8 
 9 
))((* T1T SSSSIXXX S
−⊥ −== P    (3) 10 
 11 
2.2.1.1. External Parameter Orthogonalisation (EPO) 12 
 This unsupervised orthogonalisation method uses pure spectra (without reference value) to 13 
define a basis of the space spanned by the 'interfering' factors, this way estimating the parasitic 14 
subspace X-k [19]. PCA is applied to D, containing spectra collected while the perturbation factor is 15 
varying. Retaining only the first ga PC's, the column vectors of the matrix of eigenvectors G will 16 
represent an orthonormal basis of the subspace to be removed. Subsequently, an orthogonal 17 
projection is defined to filter the calibration spectra X to obtain the 'corrected' ones (X*). 18 
 19 
)(* TGGIXX −=      (4) 20 
 21 
where G is a matrix comprising the ga first eigenvectors of the square matrix [ ]DDT . 22 
 23 
Because the original calibration data base X is adjusted by means of orthogonal projection, the 24 
correction is embedded into the model. Hence, there is no need to reapply the correction to new 25 
spectra when using the model. Advantages of this method are the high flexibility and the fact that it 26 
does not require corresponding y values. Because it is based on external a priori information, the 27 
success of the unsupervised orthogonalisation will strongly depend on how one is able to identify the 28 
detrimental spaces within the variables space, without interfering with the useful space. It will 29 
depend on the comprehensiveness of the a priori spectral information and on the empirical tuning 30 
for identifying the information to be removed. In practice, the latter can be supported by assessing 31 
the RMSECV as a function of ga and the number of latent variables, or by the evolution of the Wilks 32 
lambda value [19]. Nevertheless, using unsupervised orthogonal projection methods holds a risk of 33 
6 
 
removing too much information, i.e. when there is detrimental information not independent with 1 
the net analyte signal [20]. 2 
 3 
2.2.1.2. Orthogonal Signal Correction (OSC)  4 
OSC intends to subtract those factors from the calibration matrix X which capture the 5 
variability in X orthogonal to y (supervised orthogonalisation) [21]. It uses a PLS-NIPALS-like 6 
algorithm, where the weighted regression vector w is adjusted. Thus, OSC pre-processing involves 7 
two major steps, i.e. (1) estimation of the vector pair (t,w) for which twT explains maximum variance 8 
in X orthogonal to y, and (2) removal of the contribution of the identified component from X. 9 
 10 
)(* TtpXX −=          (5)  11 
 12 
Then, the newly obtained X* can be calibrated on y by means of PLS. Different approaches have been 13 
proposed for estimating the score vector t. As the orthogonal projection is not embedded in the 14 
calibration model, it has to be applied to new spectra prior to applying the calibration model [17]. 15 
 16 
2.2.1.3.  Net Analyte Pre-processing (NAP) 17 
 This method was introduced by Goicoechea and Olivieri [22]. To obtain an estimate of the 18 
parasitic subspace X-k, the following orthogonal projection of X to y is performed.  19 
 20 
XyyyyIX TT ))(( 1−− −=estk     (6) 21 
 22 
In a next step, X is projected orthogonal to the matrix U, consisting of the first ga PC's of X-kest to 23 
obtain X* for calibration on y  by means of PLS or CLS.  24 
 25 
)(* TUUIXX −=      (7) 26 
 27 
The same transformation is applied to new spectra x prior to applying the calibration model. 28 
 29 
xx )(* TUUI −=      (8) 30 
 31 
Thus, NAP has in common with OSC that it attempts removing the spectral information in X that is 32 
orthogonal to y (supervised orthogonalisation methods). Yet both methods use different routes to 33 
reach this goal. Compared to unsupervised orthogonalisation methods, OSC and NAP allow removing 34 
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the detrimental subspace in a less empirical way, and may also work efficiently when detrimental 1 
and useful information are not independent [20]. A disadvantage is that all the variation to be 2 
removed should be present in the calibration base, thus corresponding y values are necessary. 3 
Because of their close relationship to PLS, it has been repeatedly demonstrated that these methods 4 
can reduce the complexity of the PLS regression model, but do not enhance its predictive power [22-5 
24]. 6 
 7 
3. Experimental 8 
 9 
3.1. NIR spectroscopy 10 
Tablets were analyzed using a FT-NIR spectrometer (MPA, Bruker, Ettlingen, Germany). 11 
Spectra were collected in the 10000-5700 cm-1 region with a resolution of 8 cm-1 and averaged over 12 
16 scans. The effective sample size was approximately 11% of the tablet. It was assumed that the API 13 
was uniformly distributed in the tablet, which was confirmed by studies during method 14 
development.  15 
 16 
3.2. HPLC 17 
HPLC was used as the reference technique. All HPLC measurements were performed at 18 
Janssen Pharmaceutica, Beerse, Belgium, using their developed and validated method (confidential). 19 
 20 
3.3. Data analysis 21 
PCA, PLS regression and OSC pre-treatment were performed in Matlab 7.1. (The Mathworks, 22 
Nattick, MA) using the PLS toolbox 6.2. (Eigenvector Research, Wenatchee, WA). EPO, ACLS and NAP 23 
were directly programmed in Matlab. Minitab 16 (Minitab, PA) was used for testing the statistical 24 
significance of the predictions by the different models. 25 
 26 
3.3.1. Model development and validation 27 
The calibration set consisted of oblong shaped tablets of 6 target API concentration levels, 28 
i.e. 0, 25, 50, 100, 150 and 187.5 mg API with respective 0, 7.28, 14.56, 29.12, 38.83 and 48.54% ww-1 29 
per tablet. Tablets at the extreme concentration levels originated from laboratory batches, and were 30 
manufactured to extend the concentration range spanning the chemical variability within the 31 
specification limits. The tablets at the other concentration levels were manufactured in a production 32 
line and represent tablets to be marketed. As the calibration set contained a large concentration 33 
range, the tablet composition also varied over the concentration levels. 34 
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The NIR spectra were limited to the 9000-7600 cm-1 range and were pre-processed with standard 1 
normal variates (SNV). Except for the ACLS and NAP-CLS models, all other calibration models were 2 
built with PLS. Mean-centering was always performed prior to PLS modelling. The optimal number of 3 
latent variables for each model was selected based on the minimal RMSECV from 'leave-one-batch-4 
out' cross validation. Two independent test sets were used for external model validation. Test set 1 5 
consisted of 54 tablets, originating from 4 new production batches (one for each dose to be 6 
marketed) and 2 laboratory batches at the extreme concentration levels. In test set 2 (30 tablets 7 
from 4 production batches) strong water variations were introduced by storing the tablets at 8 
different conditions (see further in 3.3.2.). The root mean square error of prediction (RMSEP) was 9 
used as the performance criterion to assess and compare the predictive abilities of the different 10 
models. The significance of differences in prediction power was assessed by a two-way ANOVA, 11 
performed on the absolute values of the prediction errors [25]. Multiple comparisons were 12 
performed by the Dunnett's test, using the PLS model as a control to calculate p values. 13 
 14 
3.3.2. Available prior information 15 
NIR spectra were recorded from the pure tablet components, i.e. from the API (A) and the excipients 16 
(B). Fig.1 shows the obtained spectra in the considered spectral range after SNV pre-processing. 17 
10086 NIR spectra from tablets originating from 27 different production batches (i.e. for doses to be 18 
marketed: 3 batches at 7.28 % w/w, 12 batches at 14.56 %w/w, 7 batches at 29.12 % w/w and 5 19 
batches at 38.83 % w/w) were measured. They included tablets produced during pharmaceutical 20 
development and clinical trials. They also included characterization batches, produced at the limits of 21 
the critical process settings, to increase the spectral variability originating from process variability. 22 
Since hundreds of tablets per batch were measured, systematic variations in the spectra due to 23 
process variation over time may also be covered. The NIR spectra of the tablets originating from 24 
laboratory batches (at the extreme target API concentration levels) were added to this matrix, 25 
creating C (10213 x 364). 107 spectra from processed tablets with deliberate strong water variations 26 
were measured (Fig.2). Either the tablets were stored for 30 min at 50°C (to decrease the water 27 
content in the tablets), either for 3h at 75% RH, or for 16h at 75% RH (to increase the water content 28 
in the tablets).  29 
 30 
3.4. Strategies for efficient use of the prior information 31 
 32 
3.4.1. Identifying the information to be removed (clutter) 33 
 The strategies applied in this paper do not require exact knowledge of all perturbation 34 
sources, but just need a representative estimate of the spectral variation to be expected in tablets 35 
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from future batches. This can be obtained by making use of the extremely fast and simple NIR 1 
analysis, where far more tablets could be analyzed than what would be possible with HPLC. Fig.3 2 
shows a PCA score plot (PC1 versus PC2) of samples from randomly selected batches (coloured 3 
markers) for calibration of the initial PLS model, and all the prior spectral information C (10213 x 364) 4 
are in grey dots. The scores for C indicate a generally higher spread for the production batches, and 5 
this was confirmed for the following investigated PC's as well (not shown). The PCA score plots of the 6 
spectra of C from tablets at each target concentration level also showed clear systematic effects 7 
between and within production batches. Examples are shown in Figs. 4-5. An interesting example of 8 
intra-batch variability is shown in Fig.4, where the spectra from the batch marked with blue squares 9 
showed two separate clusters. This may be due to a systematic effect that occurred over the 10 
manufacturing time of the batch. Hence, selecting the samples for calibration holds a risk of not fully 11 
covering the spectral intra- and inter-batch variation that may be present in future samples. 12 
 As the variation in C is partly due to differences in API content (the parameter to be 13 
quantified) in each individual tablet, this spectral information cannot be used 'as such' for defining 14 
the clutter for the proposed strategies. Many correction methods define the clutter by the difference 15 
spectra at various perturbation levels, which works well when the property to be determined can be 16 
held constant [17]. Here, it is impossible to obtain individual tablets, even from the same batch, with 17 
exactly the same API concentration and tablet composition. Another possibility is using a y-gradient 18 
method to select the spectra for calculating the difference spectra [26], but no y-reference values are 19 
available for the massive amount of prior spectral information. For the present case study, we 20 
proposed another methodology to obtain a relevant estimate of the clutter. To correct C for known 21 
chemical variations, the pure spectra from the tablet constituents were used to calculate a basis. 22 
Removal of their spectral contributions from C was performed by orthogonal projection [18]. After 23 
the correction of C, the spectra have lost their initial form, leaving only the spectral shapes from 24 
other variations (Fig.6). 25 
 Fig.7 schematically illustrates the different tested strategies for obtaining a clutter. Matrix B 26 
(tablet excipients) can be defined as a clutter containing the known chemical noise. Considering both 27 
A and B for the orthogonal correction renders a clutter containing only the physical variations and 28 
unknown chemical variation (e.g. water content...) (D). Using A yields a clutter containing physical 29 
variations and chemical variability caused by all 'interfering' excipients (E).  30 
 31 
3.4.2. Strategies using EPO  32 
 Depending on how the clutter is defined, there are different possibilities to perform EPO 33 
corrections on the calibration spectra X (Fig.7). In a similar way as above, EPOchem directly removes 34 
the known interfering chemical variations (B) from the X spectra. In EPOglob the expected chemical 35 
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and other variations were captured in E for global EPO correction of X. Here, optimization of the 1 
dimension of the subspace to be withdrawn was performed by analyzing the evolution of the 2 
RMSECV as a function of ga and the number of LV's [19]. 3 
 4 
 3.4.3. Strategies using data augmentation  5 
 Noise augmentation (NA) of the calibration set was obtained by adding the mean-centered 6 
spectra of D to n repetitions of the original calibration spectra X. Similarly, yaug was developed as n 7 
repetitions of y, because the added spectral variations are not supposed to change the 8 
corresponding y value of each spectrum (Fig.7). Hence, a calibration set containing 10213 objects was 9 
obtained and used for PLS regression.  10 
 Because OSC and NAP need a calibration data base to calculate the orthogonal projection, 11 
these techniques were applied on the augmented calibration set, i.e., Xaug and yaug containing the 12 
most complete information. The OSCaug used the Xaug and yaug calibration base for calculating the 13 
orthogonal correction. The NA-NAP strategies performed NAP on the augmented calibration base 14 
Xaug and yaug this way calculating a projection factor to transform the spectra in X to X* prior to PLS or 15 
CLS regression. The optimal number of factors ga to be removed was determined via the minimal 16 
RMSECV. The test set spectra underwent the same transformation as the calibration spectra. 17 
 18 
3.4.4. Strategies using ACLS 19 
 The SRACLS procedure described in [14] was used to define an augmented pure component 20 
matrix K consisting of the pure spectra from the API (A) and the excipients (B), and the p first loading 21 
vectors from the residual matrix EA. In the PACLS procedure the augmented pure component matrix 22 
of the SRACLS procedure was further augmented with the k first loading vectors from D. The optimal 23 
p and k were determined through cross-validation (minimal RMSECV).  24 
 25 
3.5. Model update for strong water variations 26 
To assess whether the strategies using prior spectral information can account for strong 27 
water variations, 2 different model update strategies were proposed. In model update 1, the spectra 28 
of such processed tablets were added (with corresponding reference values) to the calibration set 1 29 
to obtain an updated calibration set containing 197 samples (120 initial + 77 processed samples). The 30 
prior information contained, just as in the previous section, no spectra of processed tablets. In model 31 
update 2, the initial training set 1 (120 not-processed tablets) was used for calibration. The prior 32 
information matrix containing intra- and inter-batch variability was augmented with spectra from 33 
processed tablets to account also for the strong water variations.  34 
 35 
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4. Results and discussion 1 
 2 
4.1. Models using prior information containing intra- and inter-batch variation 3 
In this section, the above discussed strategies were applied to evaluate their capability for 4 
filtering the intra- and inter-batch effects hampering the model performance. Test set 1 was used to 5 
evaluate the model's ability to withstand unknown variability (external validation). With PLS models 6 
covering different amounts of variation in their calibration set as a benchmark, the performance of 7 
the investigated modelling strategies was investigated in terms of number of latent variables (LV's), 8 
root mean square error of prediction (RMSEP) and its statistical significance (Table 1). The number of 9 
factors used for the correction method was also reported. All models were trained on 4 different 10 
sample sets, holding different amounts of variation. Set 1 (120 tablets, 12 batches) contained the 11 
most intra- and inter-batch variation, while set 4 (18 tablets, 6 batches) contained the least. Sets 2 12 
(60 tablets, 6 batches) and 3 (30 tablets, 6 batches) contained more intra-batch variation compared 13 
to set 4. The prior information matrix C was considered to be representative for intra- and inter-14 
batch variability in the spectra. 15 
The PLS, NAP-CLS, NAP-PLS and OSC-PLS models did not use any prior information and were 16 
added for comparison purposes. They were marked in Table 1 with an asterisk. For all calibration sets 17 
the OSC-PLS, NAP-PLS and NAP-CLS models were generally more parsimonious (less LV's) compared 18 
to PLS, but did not show improved predictive power. Many papers present similar conclusions on this 19 
behavior of OSC and NAP [22-24]. PLS established higher prediction errors in models calibrated on 20 
sample sets containing less variability. 21 
 The prediction performances of the ACLS models (SRALCS and PACLS) were much worse than 22 
the PLS-based models, making the latter models more suitable for the present case study. It is 23 
hypothesized that ACLS models, based on a linear-additive model may have trouble capturing the 24 
physical differences between the NIR spectra of powders (pure components) and tablets. They might 25 
be more suitable for modelling pure mixtures of different components [14]. Augmenting the 26 
calibration set prior to PLS, i.e. by noise addition (NA)-PLS, yielded models with more LV's compared 27 
to the original PLS models. This can be attributed to more spectral variation being included in the 28 
calibration set. Noise augmentation before PLS regression (NA-PLS), making the calibration matrix 29 
very large (10213 objects) and noisy, could not significantly enhance the prediction performance 30 
either, nor could OSC when applied on this augmented calibration matrix (NA-OSC-PLS). NA-NAP-PLS 31 
showed a statistically better prediction performance than the PLS model (p < 0.05), with a 34-40% 32 
lower RMSEP, while needing less latent variables. A similar behavior of this approach was also seen 33 
on all other calibration sets with a progressively smaller size (Table 1).  34 
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 Compared to NA-PLS, adding the NAP pre-processing seems to be advantageous for making 1 
the model more parsimonious and for improving the prediction performance. Nadler and Coifman 2 
[27] concluded that PLS may behave differently in two idealized settings: for a noise-free training set 3 
the regression vector computed by PLS is, up to normalization, the net analyte signal, while for a 4 
noisy infinite training set the regression vector is not purely proportional to the NAS vector, but is 5 
optimal under a mean squared error of prediction criterion. Considering the obtained results, it may 6 
be speculated that NAP may have a different relationship towards PLS in the augmented calibration 7 
set. It would be an interesting topic of further study to find out why the NAP algorithm performs so 8 
much better on the large and noisy augmented calibration sets, and actually allows here an 9 
improvement in prediction performance.  10 
Compared to NAP-PLS, the NA procedure may add more variability into the calibration data 11 
base, which is missing when using non-exhaustive calibration. In the NAP-CLS and NAP-PLS models 12 
only 7 to 8 factors were removed by the NAP procedure, whereas the NA-NAP operation removed 13 
between 10 and 12 factors, and approximately 1-3 additional factors were needed for subsequent 14 
PLS regression. This may approximate the number of perturbation factors to be expected in future 15 
tablets. Hence the augmentation step is also necessary to make the model more robust and the 16 
completeness of the clutter is an important factor for the performance and robustness of the 17 
models.  18 
Except for the model calibrated on set 4 the NA-NAP method performed clearly better when 19 
combined with PLS instead of CLS. In these cases, PLS was able to further model the important 20 
information. In case of calibration set 4, the NA-NAP operation returned the original calibration 21 
spectra X into X* containing almost exclusively information on the component to be quantified 22 
(Fig.8), with PLS and CLS giving a comparable result. 23 
Compared to PLS, EPO-PLS based calibrations showed lower RMSEP's and needed a lower 24 
number of LV's, and especially for models calibrated on sample sets carrying fewer variability there 25 
was a statistical difference between both approaches. Considering only the chemical variations in the 26 
correction, i.e. EPOchem, allowed improving the model performance to some extent. This can be 27 
attributed to the correction for the changing tablet compositions over the API target concentration 28 
levels, as well as for excipient inhomogenities among individual tablets.  29 
 30 
4.2. Deliberate water variation (model update) 31 
When the tablets are processed, i.e. stored at different extreme temperature and humidity 32 
conditions, the water content in the tablets can change considerably [6]. Compared to the tablets 33 
that were stored under normal conditions, those stored long in high humidity conditions (i.e. 75% 34 
RH) showed an interesting effect in their NIR spectra, i.e. shifts in the API absorption signals were 35 
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visible (Fig.2). These frequency shifts may suggest a different hydrogen bonding state of the API [28]. 1 
As this variation affects the PLS model predictions (Table 2), we investigated whether this 2 
information might be considered in the calibration base or in the clutter for a model update. 3 
 In case the model was updated by adding deliberate water variation to the calibration data 4 
base, the NA-NAP-PLS strategy again outperformed the others, and was the only model being 5 
statistically significantly better than PLS (Table 2, update 1). With a model requiring only 4 LV's an 6 
RMSEP of 0,380 for test set 1 and one of 0,385 for test set 2 were obtained. Hence the model was 7 
able to predict perturbed samples reasonably well (test set 2), while also not substantially reducing 8 
the prediction performance for normal or unperturbed samples (test set 1). Compared to NA-NAP-9 
CLS, NA-NAP-PLS allowed a lower RMSEP for both test sets. The NA-NAP-PLS model now required 1 10 
LV more than before model update (Table 1, set 1), which it probably needs to model the shifting of 11 
the API absorption signals. 12 
 The second model updating strategy included the spectra of the perturbed samples in the 13 
prior spectral information matrix. As expected, models using no prior information from processed 14 
tablets, i.e. PLS, NAP-CLS, NAP-PLS, OSC-PLS, SRACLS and EPOchem-PLS, displayed poor prediction 15 
performance for test set 2 (Table 2, update 2). This could be attributed to the fact that they did not 16 
take into account the deliberate water variation. Although some of the modelling strategies that 17 
used prior information from processed tablets were able to get better prediction errors for test set 2, 18 
the overall model performance was low and none of the methods performed significantly better than 19 
PLS. Compared to the models updated with strategy 1, none of the methods in model update 2 was 20 
able to obtain good prediction results for test set 2. The prediction performance for test set 1 21 
remained reasonably well in all models (except for PACLS), whereas predictions for test set 2 were 22 
always poor. The reason for this was found to be that the spectral perturbations due to strong water 23 
content variations in C (also causing shifting of the API absorption signals) are not completely 24 
independent of y, and therefore could not be considered in the model update. The proposed method 25 
to define the clutter (step 1 of the strategy, see section 4.1.1) uses unsupervised orthogonal 26 
projections with the pure component spectra. These may remove that part of C, which is co-linear to 27 
y, making it not possible to fully consider this kind of spectral variation in the clutter. These results 28 
demonstrate that the proposed strategies only allow making the model more robust for spectral 29 
variation that is not co-linear with the one from the property of interest. Hence, this variability 30 
should still be considered in the calibration set. 31 
 32 
5. Conclusions 33 
 When developing a NIR model for routine quality control that needs to operate over a longer 34 
time course, it may not be evident to cover all possible perturbation factors in the calibration set. 35 
14 
 
Because it is difficult to select samples describing intra-and inter-batch variability and to decide when 1 
the calibration set is representative, this study explored whether the judicious use of such prior 2 
spectral information during model development can improve the performance of NIR models for 3 
predicting the API content in tablets. The proposed strategies did neither require exact knowledge of 4 
the perturbation levels (only controlled variability of the considered perturbations was necessary), 5 
nor needed extra reference analyses.  6 
 Rather than exhaustive calibration, a more cost-effective model development approach was 7 
aspired. A massive amount of prior spectral information on intra- and inter-batch variation was 8 
obtained to allow a more representative view of the possible disturbing (i.e. systematic) effects to be 9 
encountered in the NIR spectra of tablets from a routine production. The best approach (NA-NAP-10 
PLS) consists of four essential steps. First, the disturbances to be removed are identified by means of 11 
using an orthogonal projection of pure component spectra (API and excipients) to those of the 12 
tablets containing representative intra- and inter-batch variability. This way, the known chemical 13 
variation is removed from the spectra leaving only the other variations. These mean-centered 14 
variations are in a second step added to n repetitions of the spectra of X for calibration (noise 15 
augmentation) to increase the variability in the existing calibration database. In a third step, net 16 
analyte pre-processing is used to remove those variations in Xaug that are orthogonal to yaug, in order 17 
to obtain a better estimate of the NAS. Finally, in a fourth step the orthogonally corrected X spectra 18 
are regressed to y by PLS regression.  19 
 Compared to PLS, a statistically significant improvement in prediction performance and a 34-20 
40% reduction in RMSEP was obtained for predicting new tablets with unknown intra- and inter-21 
batch variability. The model needed a minimal amount of calibration samples and latent variables. It 22 
would be interesting to further study the behavior of NAP-PLS in very large and noisy calibration 23 
matrices. 24 
 Where PLS models need the calibration set to be as complete as possible, models using prior 25 
spectral information require completeness of their clutter. This was also demonstrated by updating 26 
the model for strong water content variations in the tablets. The latter caused frequency shifts of the 27 
API absorption signals that could not be included in the clutter, resulting in reduced performance of 28 
the proposed strategies for this kind of variation. It also revealed a limitation of the method: the 29 
spectral variance that is co-linear with the wanted variation could not be considered in the clutter 30 
and should be considered in the calibration set. 31 
15 
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Figure captions 1 
 2 
Fig. 1. NIR spectra of the pure tablet components (SNV pre-processed) in the range 9000-7600 cm-1. 3 
 4 
Fig. 2. NIR spectra of processed and unprocessed tablets (SNV pre-processed) in the range 9000-7600 5 
cm-1. Spectra from unprocessed tablets are in grey, from tablets stored for 30 min at 50°C in green, 6 
from tablets stored for 3h and 16h at 75% RH in purple and red, respectively. The black ellipses 7 
indicate visible shifting of the API absorption signals. 8 
 9 
Fig. 3. PCA score plot (PC1 versus PC2) from C covering the 10213 spectra of tablets from 27 different 10 
batches (in grey). The spectra used in the calibration set 1 are represented by differently coloured 11 
markers according to their batch. 12 
 13 
Fig. 4. PCA score plot (PC1-PC2-PC3) of NIR spectra (SNV pre-processed) from tablets with 25 mg 14 
target API concentration manufactured in a production line. The different batches are indicated with 15 
differently colored markers. 16 
 17 
Fig. 5. PCA score plot (PC1-PC2-PC3) of NIR spectra (SNV pre-processed) from tablets with 100 mg 18 
target API concentration manufactured in a production line. The different batches are indicated with 19 
differently colored markers. 20 
 21 
Fig.6. Spectra before (A) and after (B) orthogonal correction using the pure component spectra of the 22 
API and excipients to remove the known chemical variations. 23 
 24 
Fig.7. Flow chart depicting the applied methodologies. A, B and C are matrices containing prior 25 
information; the subscript c represents mean-centered matrices. X (measured spectral absorbances 26 
J) and y (concentrations to be predicted P) represent the original calibration set. Xaug and yaug are the 27 
noise augmented calibration set. ⊥P represents orthogonal projection and X* is the calibration 28 
matrix returned after correction. K is the matrix of pure component signals at unit concentration.  29 
 30 
Fig. 8. Calibration spectra Xnap* (18 x 364) of set 4 after NA-NAP transformation. These spectra were 31 
subsequently calibrated on y with PLS. The different colors represent the different API concentration 32 
levels. 33 
 
   
   
   
   
   
   
   
   
Table 1. Prediction performance (for test set 1) of the different models calibrated on sample sets 
with different variation. The matrix with prior intra- and inter-batch variation was C (10213 x 364). 
The best prediction results are in bold. 
Calibrat
ion set 
Set 1 (120 tablets, 12 
batches) 
Set 2 (60 tablets, 6 
batches) 
Set 3 (30 tablets, 6 
batches) 
Set 4 (18 tablets, 6 
batches) 
Model # 
fact
ors 
# 
L
V 
RMS
EP 
p 
valu
eb 
# 
fact
ors 
# 
L
V 
RMS
EP 
p 
valu
eb 
# 
fact
ors 
# 
L
V 
RMS
EP 
p 
valu
eb 
# 
fact
ors 
# 
L
V 
RMS
EP 
p 
valu
eb 
PLSa 
 
- 7 0.58
6 
- - 4 0.63
0 
- - 4 0.63
6 
-  - 4 0.66
3 
- 
NAP-
CLSa 
 
7 - 0.54
7 
0.84
9 
8 - 0.73
9 
0.54
3 
7 - 0.75
5 
0.51
2 
7 - 1.12
6 
<0.0
01c 
NAP-
PLSa 
 
7 4 0.60
1 
1.00
0 
8 5 0.60
8 
1.00
0 
7 4 0.60
4 
0.80
7 
7 4 1.12
3 
<0.0
01c 
OSC-
PLSa 
 
3 4 0.56
0 
1.00
0 
3 5 0.64
6 
0.98
6 
1 3 0.63
6 
1.00
0 
1 3 0.66
3 
0.99
9 
NA-PLS 
 
- 8 0.49
6 
0.92
8 
- 5 0.58
8 
1.00
0 
- 6 0.56
6 
0.96
3 
- 6 0.58
5 
0.98
5 
SRACLS 
 
5 - 0.65
9 
0.99
4 
10 - 1.25
4 
<0.0
01c 
6 - 0.97
5 
<0.0
01c 
6 - 0.98
8 
<0.0
01c 
PACLS 
 
5-1 - 0.90
8 
<0.0
01c 
8-1 - 1.09
9 
<0.0
01c 
6-1  0.94
5 
<0.0
01c 
6-1 - 1.13
9 
<0.0
01c 
EPOchem
-PLS 
 
4  5 0.51
1 
0.71
6 
4  4 0.46
8 
0.01
3c 
4  5 0.48
7 
0.10
7 
4  5 0.51
9 
0.28
1 
EPOgl-
PLS 
 
1 6 0.46
1 
0.44
9 
1 7 0.58
1 
1.00
0 
1 6 0.47
8 
0.00
4c 
1 7 0.51
6 
0.00
9c 
NA-
NAP-
CLS 
 
10 - 0.57
2 
1.00
0 
12 - 0.52
7 
0.58
8 
11 - 0.54
6 
0.37
0 
11 - 0.43
4 
0.02
6c 
NA-
NAP-
PLS 
 
10 3 0.38
8 
0.02
7c 
12 2 0.40
7 
0.00
7c 
11 2 0.38
2 
<0.0
01c 
11 1 0.43
1 
0.01
5c 
NA-
OSC-
PLS 
2 3 0.48
8 
0.69
7 
1 2 0.54
6 
0.58
6 
1 2 0.53
3 
0.42
4 
1 2 0.56
4 
0.72
7 
                 
a These models did not use prior information; they used only information from the calibration set 
b p values (Dunnett's test) for the significance testing by two-way ANOVA of the predictive ability 
compared to PLS 
c Indicates significantly lower absolute prediction errors on significance level α=0.05 
 
  
Table 2. Prediction performance (for test sets 1 and 2) after model update for deliberate water variations. The 
best prediction results are in bold. 
 Update 1 Update 2 
Model # 
factors 
# 
LV 
RMSEP 
test set 
1 
RMSEP 
test set 
2 
p 
valueb 
# 
factors 
# 
LV 
RMSEP 
test set 
1 
RMSEP 
test set 
2 
p 
valueb 
PLSa 
 
- 8 0.632 0.407 - - 7 0.586 1.274 
 
- 
NAP-CLSa 
 
8 - 0.534 0.461 0.883 7 - 0.547 1.488 
 
1.000 
NAP-PLSa 
 
8 6 0.644 0.302 0.645 7 4 0.601 1.358 
 
1.000 
OSC-PLSa 
 
5 6 0.632 0.346 0.989 3 4 0.560 1.506 1.000 
NA-PLS 
 
- 8 0.548 0.433 0.549 - 5 0.466 0.854 0.844 
SRACLSa 
 
9 - 0.780 0.466 0.124 5 - 0.659 1.557 1.000 
PACLS 
 
9-1 - 0.756 0.417 0.067 5-12 - 5.490 8.323 <0.001c 
EPOchem-PLS
a 
 
4  5 0.575 0.376 0.792 4  5 0.511 0.913 0.948 
EPOgl-PLS 
 
1 7 0.516 0.397 0.284 1 7 0.549 0.977 0.989 
NA-NAP-CLS 
 
11 - 0.512 0.517 0.964 13 - 0.567 
 
0.728 
 
0.923 
NA-NAP-PLS 
 
11 4 0.380 0.385 0.003c 13 3 0.488 
 
0.761 
 
0.595 
NA-OSC-PLS 4 2 0.498 0.409 0.265 1 2 0.510 0.976 0.966 
aThese models did not use prior information of processed tablets containing deliberate water variations.bp 
values (Dunnett's test) for the significance testing by two-way ANOVA of the predictive ability compared to PLS. 
cIndicates significantly lower absolute prediction errors on significance level α=0.05. 
  
   
Highlights:  
- a cost-effective NIR model development strategy is proposed for API content prediction in 
tablets 
- judicious use of prior spectral information improves PLS model performance  
- the clutter captures representative intra- and inter-batch spectral variability to be removed 
- model requires completeness of the clutter rather than comprehensive calibration sets 
 
 
